Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levulan PDT for AK and NMSC Prevention in Transplant Recipients
NCT03110159Phase 2Completed
- Start
- Aug 2017
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aminolevulinic acid in actinic keratosis (AK) and non-melanoma skin cancer (NMSC). Primary endpoint: Primary prevention of Actinic Keratosis at 3 years. Started Aug 2017; status: completed.
02
Drugs
aminolevulinic acid
03
Conditions
actinic keratosis (AK)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT03110159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110159.